LXRX
LEXICON PHARMACEUTICALS, INC.
NASDAQ · Healthcare · Biotechnology · US
$2.05
+0.74%Aug 24, 2026, 12:30 UTC
Lexicon Pharmaceuticals earned a $10 million milestone payment from Novo Nordisk after achieving a key Phase 1 development milestone for LX9851, an oral non-incretin obesity candidate being developed by Novo Nordisk.
Source:Aug 6, 2026, 21:05 UTC
Lexicon Pharmaceuticals completed enrollment in its Phase III SONATA-HCM trial.
Source:Aug 6, 2026, 11:30 UTC
Lexicon Pharmaceuticals reported financial results for the second quarter of 2026.